Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2021

View Archived Issues

A different path to specificity for Ras inhibitors

Crinetics opens phase III study of paltusotine to treat acromegaly

LIB Therapeutics initiates phase III studies of lerodalcibep in hypercholesterolemia

BioNTech and Regeneron evaluate the combination of BNT-111 and cemiplimab in melanoma

Anti-CD6 therapy suppresses autoimmunity and enhances cancer cell death

Characterization of HSK-16149, a selective ligand of VGCC alpha2delta subunit

Phase I trial of a vaccine targeting tumor-associated antigens PSA, MUC-1 and brachyury in mCRPC

Adrenaline release immobilizes immune cell responses

Gene variants linked to premenstrual dysphoric disorder

IL-12 immunoconjugate SON-1010 generally well tolerated in cynomolgus monkeys

FDA clears IND application for PF-614-MPAR opioid with overdose protection

Patient dosing begins in phase Ib/II study of CFI-400945 in leukemia

European Commission approves Orladeyo for the prevention of HAE attacks

New model of metabolic syndrome-induced CKD in mice

Janssen Pharmaceutica divulges CB1 and/or CB2 receptor agonists

Esteve Pharmaceuticals patents new analgesics

Monte Rosa Therapeutics discloses new protein cereblon modulators

Heptares Therapeutics presents EP4 receptor antagonists

U.S. researchers discover new CARs against cytomegalovirus

FDA approves Farxiga for chronic kidney disease

FDA approves Ferriprox to treat transfusional iron overload due to sickle cell disease

Researchers identify new markers of treatment response in alcohol use disorder

FDA issues complete response letter for tralokinumab in moderate to severe atopic dermatitis

Synairgen reports home cohort and combined analysis from phase II trial of SNG-001 in COVID-19

Repare initiates phase I trial of oral PKMYT1 inhibitor RP-6306

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...